Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
DVAX's Cash-to-Debt is ranked higher than
97% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. DVAX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
DVAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.34  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.88
DVAX's Equity-to-Asset is ranked higher than
68% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. DVAX: 0.88 )
Ranked among companies with meaningful Equity-to-Asset only.
DVAX' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.28  Med: 0.76 Max: 0.93
Current: 0.88
-2.28
0.93
Interest Coverage No Debt
DVAX's Interest Coverage is ranked higher than
96% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. DVAX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
DVAX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: -0.39
Beneish M-Score: -1.28
WACC vs ROIC
3.91%
-3420.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1062.20
DVAX's Operating Margin % is ranked lower than
77% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. DVAX: -1062.20 )
Ranked among companies with meaningful Operating Margin % only.
DVAX' s Operating Margin % Range Over the Past 10 Years
Min: -2594.4  Med: -547.7 Max: -37.49
Current: -1062.2
-2594.4
-37.49
Net Margin % -1080.18
DVAX's Net Margin % is ranked lower than
78% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. DVAX: -1080.18 )
Ranked among companies with meaningful Net Margin % only.
DVAX' s Net Margin % Range Over the Past 10 Years
Min: -2636.89  Med: -509.28 Max: -56.15
Current: -1080.18
-2636.89
-56.15
ROE % -92.55
DVAX's ROE % is ranked lower than
74% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. DVAX: -92.55 )
Ranked among companies with meaningful ROE % only.
DVAX' s ROE % Range Over the Past 10 Years
Min: -307.22  Med: -77.84 Max: -49.94
Current: -92.55
-307.22
-49.94
ROA % -77.27
DVAX's ROA % is ranked lower than
77% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. DVAX: -77.27 )
Ranked among companies with meaningful ROA % only.
DVAX' s ROA % Range Over the Past 10 Years
Min: -85.08  Med: -52 Max: -19.74
Current: -77.27
-85.08
-19.74
ROC (Joel Greenblatt) % -642.31
DVAX's ROC (Joel Greenblatt) % is ranked lower than
56% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. DVAX: -642.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DVAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1090.64  Med: -785.29 Max: -172.67
Current: -642.31
-1090.64
-172.67
3-Year Revenue Growth Rate -20.60
DVAX's 3-Year Revenue Growth Rate is ranked lower than
75% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. DVAX: -20.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DVAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -27.4 Max: 88.2
Current: -20.6
0
88.2
3-Year EBITDA Growth Rate -4.80
DVAX's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. DVAX: -4.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DVAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.3  Med: -11.5 Max: 39.1
Current: -4.8
-63.3
39.1
3-Year EPS without NRI Growth Rate -8.60
DVAX's 3-Year EPS without NRI Growth Rate is ranked lower than
58% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. DVAX: -8.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DVAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.6  Med: -18.2 Max: 26.3
Current: -8.6
-60.6
26.3
GuruFocus has detected 3 Warning Signs with Dynavax Technologies Corp $DVAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DVAX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-05 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

DVAX Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
John Paulson 174,000 sh (-12.87%)
Steven Cohen 450,346 sh (-44.00%)
Chuck Royce 164,000 sh (-45.15%)
» More
Q3 2016

DVAX Guru Trades in Q3 2016

Paul Tudor Jones 22,654 sh (New)
Steven Cohen 1,754,000 sh (+289.48%)
John Paulson 174,000 sh (unchged)
Chuck Royce 120,000 sh (-26.83%)
» More
Q4 2016

DVAX Guru Trades in Q4 2016

Jim Simons 463,951 sh (New)
Paul Tudor Jones 63,600 sh (+180.75%)
John Paulson 174,000 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 111,000 sh (-7.50%)
» More
Q1 2017

DVAX Guru Trades in Q1 2017

Steven Cohen 726,500 sh (New)
John Paulson 463,000 sh (+166.09%)
Jim Simons 574,051 sh (+23.73%)
Paul Tudor Jones Sold Out
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:OBSV, AMEX:MTNB, OTCPK:CKPT, OTCPK:MXDHF, NAS:SVA, NAS:SELB, OTCPK:TYMI, OTCPK:NICXF, NAS:VCYT, OTCPK:SIGA, NAS:PETX, NAS:IDRA, NAS:NK, NAS:KMDA, NAS:ARDX, OTCPK:CLVLF, NAS:ABEO, NAS:VYGR, NAS:NERV, NAS:CGEN » details
Traded in other countries:DYF1.Germany,
Headquarter Location:USA
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The Company is engaged in the development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer.

Dynavax Technologies Corp was incorporated in California in August 1996 under the name Double Helix Corporation, and it changed its name to Dynavax Technologies Corporation in September 1996. The Company reincorporated in Delaware in 2000. The Company is a clinical-stage biopharmaceutical company. It discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine. Its pipeline of product candidates includes: HEPLISAV, its autoimmune program partnered with GlaxoSmithKline, and its therapy for asthma partnered with AstraZeneca AB. Its product candidates are based on the use of immunostimulatory and immunoregulatory sequences. HEPLISAV is an investigational adult hepatitis B vaccine. In Phase 3 trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. The Company has worldwide commercial rights to HEPLISAV. HEPLISAV combines its first generation 1018 ISS with hepatitis B surface antigen manufactured in its facility in Düsseldorf, Germany. The Company competes with pharmaceutical companies, biotechnology companies, academic institutions and research organizations, in developing therapies to prevent or treat infectious diseases and inflammatory and autoimmune diseases. Any product candidate it develops is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA and foreign regulatory agencies.

Top Ranked Articles about Dynavax Technologies Corp

What Dynavax Technologies Holders Need to Consider Heading Into the Heplisav-B PDUFA A look at the upcoming PDUFA decision, what's come before it and some things to consider for those holding or thinking about picking up an exposure
There is a large unmet need right now in the hepatitis B space. A recent study has revealed only half of the individuals that receive hepatitis B vaccinations are actually gaining any sort of immunity to the virus. Read more...
Steven Cohen Increases Position in Dynavax Company is one of many biopharmaceutical holdings
Steven Cohen (Trades, Portfolio) of Point72 Asset Management increased his position in Dynavax Technologies Corp. (NASDAQ:DVAX) by 375.26% on Sept. 29. Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.55
DVAX's PB Ratio is ranked higher than
65% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. DVAX: 2.55 )
Ranked among companies with meaningful PB Ratio only.
DVAX' s PB Ratio Range Over the Past 10 Years
Min: 0.65  Med: 4.35 Max: 14.94
Current: 2.55
0.65
14.94
PS Ratio 20.85
DVAX's PS Ratio is ranked lower than
63% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. DVAX: 20.85 )
Ranked among companies with meaningful PS Ratio only.
DVAX' s PS Ratio Range Over the Past 10 Years
Min: 0.18  Med: 24.65 Max: 208.92
Current: 20.85
0.18
208.92
EV-to-EBIT -1.68
DVAX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. DVAX: -1.68 )
Ranked among companies with meaningful EV-to-EBIT only.
DVAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.2  Med: -3.1 Max: 6.3
Current: -1.68
-26.2
6.3
EV-to-EBITDA -1.72
DVAX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. DVAX: -1.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.3  Med: -3.2 Max: 32.5
Current: -1.72
-16.3
32.5
Current Ratio 7.24
DVAX's Current Ratio is ranked higher than
53% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. DVAX: 7.24 )
Ranked among companies with meaningful Current Ratio only.
DVAX' s Current Ratio Range Over the Past 10 Years
Min: 1.87  Med: 5.94 Max: 13.98
Current: 7.24
1.87
13.98
Quick Ratio 7.24
DVAX's Quick Ratio is ranked higher than
55% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. DVAX: 7.24 )
Ranked among companies with meaningful Quick Ratio only.
DVAX' s Quick Ratio Range Over the Past 10 Years
Min: 1.87  Med: 5.94 Max: 13.98
Current: 7.24
1.87
13.98
Days Sales Outstanding 52.17
DVAX's Days Sales Outstanding is ranked higher than
65% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. DVAX: 52.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.1  Med: 48.57 Max: 187.36
Current: 52.17
8.1
187.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.70
DVAX's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. DVAX: -13.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -180.4  Med: -29.8 Max: -9.4
Current: -13.7
-180.4
-9.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.44
DVAX's Price-to-Net-Cash is ranked higher than
70% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. DVAX: 3.44 )
Ranked among companies with meaningful Price-to-Net-Cash only.
DVAX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.85  Med: 5.17 Max: 26.38
Current: 3.44
1.85
26.38
Price-to-Net-Current-Asset-Value 3.26
DVAX's Price-to-Net-Current-Asset-Value is ranked higher than
73% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. DVAX: 3.26 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DVAX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.79  Med: 4.69 Max: 124
Current: 3.26
1.79
124
Price-to-Tangible-Book 2.60
DVAX's Price-to-Tangible-Book is ranked higher than
71% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. DVAX: 2.60 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DVAX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.73  Med: 4.25 Max: 27.68
Current: 2.6
1.73
27.68
Price-to-Median-PS-Value 0.85
DVAX's Price-to-Median-PS-Value is ranked higher than
61% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. DVAX: 0.85 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DVAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 0.8 Max: 7.95
Current: 0.85
0.02
7.95
Earnings Yield (Greenblatt) % -59.43
DVAX's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. DVAX: -59.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DVAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -61.88  Med: 58.9 Max: 3563.3
Current: -59.43
-61.88
3563.3

More Statistics

Revenue (TTM) (Mil) $10.25
EPS (TTM) $ -2.81
Beta0.28
Short Percentage of Float14.71%
52-Week Range $3.20 - 17.50
Shares Outstanding (Mil)48.79

Analyst Estimate

Dec18
Revenue (Mil $)
EPS ($) -1.21
EPS without NRI ($) -1.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for DVAX

Headlines

Articles On GuruFocus.com
What Dynavax Technologies Holders Need to Consider Heading Into the Heplisav-B PDUFA Apr 03 2017 
Trump Victory Gives Life to Pharma,Biotech - Take a Look at VBI Vaccines Nov 11 2016 
Steven Cohen Increases Position in Dynavax Oct 07 2016 
VBI Vaccines: The Safer Alternative to the Struggling Dynavax Technologies Sep 06 2016 
Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination With Merck's Anti- Oct 08 2015 
Dynavax to Participate in Two Upcoming Investor Conferences Sep 03 2015 
Dynavax Reports Second Quarter 2015 Financial Results Aug 07 2015 
Dynavax Prices Public Offering of Common Stock Jul 22 2015 
Dynavax Announces Proposed Public Offering of Common Stock Jul 21 2015 
Dynavax Secures $40 Million Credit Facility With Hercules Technology Growth Capital Dec 29 2014 

More From Other Websites
Dynavax to Present Data on SD-101 in Combination with KEYTRUDA(R) at the 2017 American Society of... May 19 2017
ETFs with exposure to Dynavax Technologies Corp. : May 11, 2017 May 11 2017
Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 May 10 2017
Dynavax Technologies reports 1Q loss May 08 2017
Dynavax Reports First Quarter 2017 Financial Results May 08 2017
ETFs with exposure to Dynavax Technologies Corp. : April 21, 2017 Apr 21 2017
William Blair Assigns 70% Probability of Approval to Dynavax's Heplisav Apr 07 2017
What Dynavax Technologies Holders Need to Consider Heading Into the Heplisav-B PDUFA Apr 03 2017
Why Dynavax Technologies Corporation Stock Briefly Spiked Today Apr 03 2017
Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B Apr 03 2017
ETFs with exposure to Dynavax Technologies Corp. : March 27, 2017 Mar 27 2017
Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017 Mar 23 2017
Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American... Mar 20 2017
Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update Mar 13 2017
3 Beaten Down Stocks Ready to Bounce Back Mar 09 2017
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle Mar 08 2017
UPDATE: Dynavax shares reverse premarket losses to open flat Mar 06 2017
Dynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the... Mar 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)